Article
Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Annals of surgical oncology - 1 Nov 2018
Theobald Kristin A, Susswein Lisa R, Marshall Megan L, Roberts Maegan E, Mester Jessica L, Speyer Darrow, Williams Ravin N W, Knapke Sara C, Solomon Sheila R, Murphy Patricia D, Klein Rachel T, Hruska Kathleen S, Solomon Benjamin D
Abstract excerpt
BACKGROUND: Knowledge of a germline pathogenic/likely pathogenic variant (PV) may inform breast cancer management. BRCA1/2 PV often impact surgical decisions, but data for multi-gene panel testing are lacking. Expedited genetic testing reduces turn-around times based on request for treatment-related decision making. This report aims to describe the clinical utility of expedited multi-gene panel testing for...
Topics
- BRCA1 Protein
- BRCA2 Protein
- Biomarkers, Tumor
- Breast Neoplasms
- Disease Management
- Female
- Genetic Predisposition to Disease
- Genetic Testing
- Germ-Line Mutation